摘要
目的 评价贝那普利联合螺内酯治疗慢性心力衰竭的有效性和安全性.方法 计算机检索PubMed、CNKI、VIP、CBD数据库中比较贝那普利联合螺内酯与贝那普利治疗慢性心力衰竭的随机对照试验.采用RevMan 5.2软件对试验结果进行Meta分析.结果 共纳入10篇文献,Meta分析的结果显示,贝那普利联合螺内酯组在临床疗效上优于贝那普利组（RR=1.23,95％CI 1.17～1.30,P＜0.01）,在改善左室射血分数（LVEF）上优于贝那普利组（SMD=1.86,95％CI 0.85～2.88,P＜0.01）,在缩小左室收缩末期内径（LVESD）上优于贝那普利组（SMD=-1.91,95％CI-2.34～-1.15,P＜0.01）,在缩小左室舒张末期内径（LVEDD）上优于贝那普利组（SMD=-2.13,95％CI-2.57～-1.69,P＜0.01）.两组不良反应的发生率未见统计学差异（RR =-0.74,95％CI 0.22～2.51,P=-0.63）.结论 贝那普利联合螺内酯治疗慢性心力衰竭的效果优于贝那普利.
Objective To evaluate the efficacy and safety of Benazepril and Aldosterone in the treatment of chronic heart congestive heart failure.Methods The databases of Pubmed,CNKI,VIP and CBD were retrieved for collecting the randomized controlled trials about the treatment of chronic heart failure with the combination of Benazepril and Aldosterone or Benazepril.Data was analyzed by RevMan 5.2 software.Results Ten studies were enrolled in this study.The meta analysis results showed that the combination of Benazepril and Aldosterone had a significantly higher efficacy than the Benazepril in term of the clinical efficacy （RR=1.23,95％CI 1.17-1.30,P＜0.01）,improvement of LVEF（SMD=1.86,95％CI 0.85-2.88,P＜0.01）,reduction of LVESD（SMD=-1.91,95％CI-2.34--1.15,P＜0.01） and LVEDD （SMD=-2.13,95％CI-2.57--1.69,P＜0.01）.There was no difference in the adverse reactions between the two groups （RR=-0.74,95％CI 0.22-2.51,P=0.63）.Conclusion The combination of Benazepril and Aldosterone has a higher efficacy than the Benazepril in the treatment of chronic heart failure.
出处
《中国心血管病研究》
CAS
2017年第8期739-743,共5页
Chinese Journal of Cardiovascular Research
基金
国家自然科学基金资助项目（项目编号：81170085）
